Aktuelle Neurologie, Table of Contents Aktuelle Neurologie 2018; 45(05): 391-393DOI: 10.1055/a-0602-8462 Kompetenznetz Multiple Sklerose © Georg Thieme Verlag KG Stuttgart · New YorkAktuelles aus der Forschung T. Menge 1 Zentrum Neurologie und Neuropsychiatrie, LVR-Klinikum, Heinrich-Heine-Universität, Düsseldorf 2 Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf , G. Meyer zu Hörste 3 Klinik für Allgemeine Neurologie, Department für Neurologie, Universitätsklinikum Münster› Author AffiliationsRecommend Article Abstract Buy Article Full Text References Literatur 1 Green AJ, Gelfand JM, Cree BA. et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 2017; 390: 2481-2489 2 Mei F, Fancy SPJ, Shen YA. et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 2014; 20: 954-960 3 Weideman AM, Tapia-Maltos SA, Johnson K. et al. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol 2017; 8: 577 4 Russi AE, Ebel ME, Yang Y. et al. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc Natl Acad Sci U S A 2018; 115: E1520-E1529 5 Wohn C, Brand A, van Ettinger K. et al. Gradual development of psoriatic skin lesions by constitutive low-level expression of IL-17A. Cell Immunol 2016; 308: 57-65 6 Spath S, Komuczki J, Hermann M. et al. Dysregulation of the Cytokine GM-CSF Induces Spontaneous Phagocyte Invasion and Immunopathology in the Central Nervous System. Immunity 2017; 46: 245-260
